Ranbaxy gains on Prilosec generic

Ranbaxy Laboratories got a welcome dose of good news as its shares climbed more than 3 percent on the launch of its generic version of the acid reflux drug Prilosec in the U.S., under an agreement with AstraZeneca. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.